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INTRODUCTION
Sudden hearing loss (SHL) is defi ned as a 
sensorineural hearing loss, equal to or greater 
than 30 dB, at three or more consecutive fre-
quencies, which takes place within 72 hours.1 
Several suggested theories attempt to elucidate 
the etiopathogenesis of SHL, including auto-
immune diseases, vascular insults, infectious 
diseases and ototoxic drugs.2-5 To our knowl-
edge hepatitis C virus has not yet been associ-
ated with SHL. Pegylated interferon in combi-
nation with ribavirin is the treatment of choice 
for patients with chronic hepatitis C. Both 
peginterferon and ribavirin are well-known 
to be associated with significant adverse ef-
fects, but SHL is uncommon. We report a 
65-year-old male patient who developed sud-
den-onset hearing loss during combination 
therapy with pegylated interferon-alpha and 
ribavirin for chronic hepatitis C.
CASE DESCRIPTION
A 65-year-old man with a history of chronic 
hepatitis C was referred to our department 
for further evaluation. He was 170 cm tall and 
weighed 74 kg. He reported to have systemic ar-
terial hypertension and had been taking hydro-
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clorothiazide 25 mg and enalapril 40 mg daily 
for two years without any adverse effects. His 
initial physical and neurological examinations 
were normal. Serum levels of glucose, urea, 
creatinine, lipids, electrolytes, alkaline phos-
phatase, bilirubin, gammaglutamyl transferase, 
blood cell count, ferritin, were within normal 
limits. Alanine aminotransferase (ALT) was 
62 UI/L (upper limit of normal < 45), aspartate 
aminotransferase (AST) was 39 UI/L (upper 
limit of normal < 45 UI/L). Antinuclear, anti-
smooth muscle, anti-liver-kidney microsome 1 
and anti-mitochondrial antibodies were nega-
tive. His viral load was 500,000 RNA IU/mL 
and the hepatitis C genotype was 1a. Liver bi-
opsy revealed chronic hepatitis with moderate 
activity and stage II fi brosis (Metavir F2-A2). 
Combination therapy was started with PEG-
IFN-α-2a subcutaneously (180 µg per week) 
and ribavirin (1,000 mg/day). The patient re-
sponded well, his aminotransferase levels nor-
malized, and HCV-RNA was undetectable at 
weeks 12 and 24.Twenty-eight weeks after initi-
ation of therapy, he suddenly developed severe 
hearing loss in the right ear. He did not com-
plain of any visual problems, dysphagia, dys-
arthria, sensory or motor defi cits. He denied 
any recent ﬂ u-like symptoms or fever, chills, 
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or night sweats. His physical examination at this time was 
otherwise unremarkable. Six days after the beginning of his 
symptoms (SHL on right ear) he was attended at the “Sud-
den Hearing Loss Section” of the Otolaryngology Depart-
ment, Hospital das Clínicas of FMSUP, São Paulo. The initial 
audiometric test showed profound hearing loss on right ear. 
He had begun SHL treatment three days after the beginning 
of the fi rst symptoms with dexamethasone 8 mg daily for 
15 days, pentoxifylline 1,200 mg and vitamin A 50,000 IU 
daily for 30 days each, prescribed during fi rst-aid clinic ap-
pointment. As the patient did not show any improvement 
with the usual SHL drug therapy, intratympanic steroids 
were proposed. Dexamethasone 2 mg was administered by 
instilling the steroid solution through the posteroinferior 
area of the tympanic membrane using a tuberculin syringe 
and a spinal needle, three times a week during two weeks; 
however, no audiometric improvement was observed. 
During routine SHL investigation blood exams revealed 
mild anemia with 10.6 g/dL hemoglobin and 33.3% he-
matocrit, bordering serum glucose 111 mg/dL and mild 
increase on ESR 23 mm. Transient-evoked (TE-OAE) and 
distortion product otoacoustic emission (DP-OAE) tests, 
usually used to check out the amplifi cation function of the 
cochlea, disclosed any outer hair cells function confi rming 
inner ear damage on the tested frequencies of 1.0; 1.5; 2.0; 
3.0 and 4.0 kHz. Electronystagmography test, usually used 
to check out the function of the vestibular system, showed 
spontaneous nystagmus of 40/second, with oculomotor 
evaluation, positioning and positional testing and caloric 
stimulation showing normal results. These fi ndings suggest 
a mild central tonus asymmetry probably due to an asso-
ciated vestibular damage. The MRI showed vascular loop 
on the right internal auditory canal which was considered 
an exam finding, not related to SHL. Despite pegylated 
IFN-alpha/ribavirin therapy interruption and the specific 
therapeutic approach to SHL there was no improvement 
of the hearing loss.
DISCUSSION
In most cases, SHL is severe, unilateral and idiopathic.1,4,6 In 
the United States, the incidence is 5-20 cases per 100,000 
inhabitants per year.1 Worldwide, SHL accounts for ap-
proximately 1% of all cases of deafness, and 15,000 new 
cases occur annually.7,8 Several viruses have been strongly 
implicated as having a causative role in the pathogenesis of 
SHL. Different authors have studied the incidence of sero-
conversion to several viruses in a group of patients present-
ing with SHL compared with a healthy control group.9,10 In 
the SHL group of patients, there was a signifi cantly higher 
incidence of seroconversion to mumps, rubella, measles, 
herpes simplex, varicella-zoster, cytomegalovirus and inﬂ u-
enza viruses types A and B. A sensory neural type of hear-
ing loss has also been reported in patients infected with 
Rickettsia rickettsii, R. typhi or R. coronii.11,12 Syphilis has also 
been frequently associated with SHL, particularly among HIV 
co-infected patients.13,14 To our knowledge hepatitis C virus 
has not yet been associated with SHL. This case report illus-
trates a rare, potentially reversible adverse reaction to pegylated 
IFN-alpha-2a/ribavirin combination therapy for chronic HCV 
infection. PEG-IFN/ribavirin treatment for chronic HCV in-
fection has been associated with many adverse effects. Neu-
rological adverse effects, including asthenia, vertigo, muscle 
cramps, cognitive impairment, irritability, depression and 
other psychological disorders are also frequently associated 
with PEG-IFN therapy.15 Rarely other neurological adverse 
effects of PEG-IFN therapy may include oculomotor nerve 
paralysis, seizures, Bell’s palsy, peripheral neuropathy and 
acute sensorineural hearing loss.16-19 To the best of our 
knowledge, this is the fi rst case that describes acute senso-
rineural hearing loss associated with PEG-IFN therapy in 
Brazil. Several factors may be associated with SHL in pa-
tients treated with interferon-alpha. Most studies have as-
sociated interferon-alpha rather pegylated interferon with 
SHL. Interferon may be directly ototoxic.20 Other studies 
have suggested that IFN through autoimmune mechanisms 
could be associated with SHL.21 Another possible cause of 
SHL could be anemia. SHL has been described in patients 
with aplastic anemia and sickle cell anemia probably as 
result of intracochlear hemorrhage and vaso-occlusive or 
inﬂ ammatory effects.22,23 Our patient presented mild ane-
mia at the time SHL was observed, however hematologic 
changes are common systemic side-effects in the course of 
PEG-IFN therapy.18 Finally, SHL in our patient could be 
just a coincidence. Hearing impairment increases with age 
and, as mentioned above, in the United States the incidence 
is 5-20 cases per 100,000 inhabitants per year.1 According 
to a recent report SHL may occur in about 1% of chronic 
hepatitis C on treatment with PEG-IFN/ribavirin combi-
nation therapy.18 This rate does not differ to that observed 
for worldwide population incidence1 and possible involved 
mechanisms include direct ototoxicity, autoimmunity, or 
hematological changes. In contrast to published cases on 
auditory disability due to standard IFN therapy, in which 
most patients usually recovered 7 to 14 days after the dis-
continuation of IFN;21 hearing loss may not fully resolve 
after discontinuation of PEG-IFN therapy.18 On the other 
hand, symptoms may not worsen on continued treatment. 
The decision whether to continue or stop treatment is not 
clear in the literature and should be based on the clinical 
judgment of the treating physician.18 In conclusion, PEG-
IFN may cause SHL that may not recover after discontinu-
ation of therapy. Immediate treatment for all possible eti-
ologies is essential, along with targeted investigations and 
early referral for an ENT (Ear, Nose and Throat) specialist. 
Physicians should be aware of the possible ototoxic effects 
of IFN-PEG requiring appropriate surveillance.
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